- Home
- CCEL vs ICCC Comparison
CCEL vs ICCC Comparison
Compare CCEL & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCEL
- ICCC
- Stock Information
- Founded
- CCEL 1989
- ICCC 1982
- Country
- CCEL United States
- ICCC United States
- Employees
- CCEL N/A
- ICCC N/A
- Industry
- CCEL Managed Health Care
- ICCC Biotechnology: Pharmaceutical Preparations
- Sector
- CCEL Health Care
- ICCC Health Care
- Exchange
- CCEL Nasdaq
- ICCC Nasdaq
- Market Cap
- CCEL 51.9M
- ICCC 46.2M
- IPO Year
- CCEL 1997
- ICCC 1987
- Fundamental
- Price
- CCEL $5.12
- ICCC $6.40
- Analyst Decision
- CCEL Strong Buy
- ICCC
- Analyst Count
- CCEL 1
- ICCC 0
- Target Price
- CCEL $8.50
- ICCC N/A
- AVG Volume (30 Days)
- CCEL 10.1K
- ICCC 25.6K
- Earning Date
- CCEL 07-14-2025
- ICCC 05-14-2025
- Dividend Yield
- CCEL 7.81%
- ICCC N/A
- EPS Growth
- CCEL N/A
- ICCC N/A
- EPS
- CCEL 0.01
- ICCC N/A
- Revenue
- CCEL $32,102,750.00
- ICCC $27,302,766.00
- Revenue This Year
- CCEL $2.49
- ICCC N/A
- Revenue Next Year
- CCEL $0.95
- ICCC N/A
- P/E Ratio
- CCEL $321.51
- ICCC N/A
- Revenue Growth
- CCEL 2.33
- ICCC 28.29
- 52 Week Low
- CCEL $4.75
- ICCC $3.34
- 52 Week High
- CCEL $9.43
- ICCC $6.84
- Technical
- Relative Strength Index (RSI)
- CCEL 48.65
- ICCC 69.17
- Support Level
- CCEL $4.79
- ICCC $6.00
- Resistance Level
- CCEL $5.15
- ICCC $6.72
- Average True Range (ATR)
- CCEL 0.17
- ICCC 0.40
- MACD
- CCEL 0.05
- ICCC 0.10
- Stochastic Oscillator
- CCEL 63.79
- ICCC 78.64
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.